• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Breast cancer].[乳腺癌]
Rev Med Panama. 1995 Jan-May;20(1-2):50-3.
2
The National Cancer Data Base report on the results of a large nonrandomized comparison of breast preservation and modified radical mastectomy.国家癌症数据库关于保乳术与改良根治性乳房切除术大型非随机比较结果的报告。
Cancer. 1997 Jul 1;80(1):162-7.
3
[Clinical analysis of resectable breast cancer: a report of 6 263 cases].可切除乳腺癌的临床分析:6263例报告
Ai Zheng. 2005 Mar;24(3):327-31.
4
Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge.乳头溢液相关乳腺癌患者保乳手术的可行性
Cancer. 2004 Aug 1;101(3):508-17. doi: 10.1002/cncr.20394.
5
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.新辅助化疗联合乳房切除术且未行放疗的II期乳腺癌患者,初诊时为T3期疾病或四个及以上淋巴结有病理累及提示局部区域复发。
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):138-45. doi: 10.1016/j.ijrobp.2003.10.037.
6
Negative margin status improves local control in conservatively managed breast cancer patients.切缘阴性状态可改善接受保守治疗的乳腺癌患者的局部控制情况。
Cancer J Sci Am. 2000 Jan-Feb;6(1):28-33.
7
[Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].[局部晚期非炎性乳腺癌的联合化疗及术前放疗治疗:120例患者的最新结果]
Cancer Radiother. 2004 Jun;8(3):155-67. doi: 10.1016/j.canrad.2004.01.001.
8
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.接受多模态治疗的局部晚期和炎性乳腺癌患者的长期随访
J Clin Oncol. 2004 Oct 15;22(20):4067-74. doi: 10.1200/JCO.2004.04.068.
9
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].一项随机对照研究,在辅助治疗背景下,比较尿嘧啶替加氟(UFT)+他莫昔芬(UFT + TAM疗法)与环磷酰胺+阿霉素+ 5-氟尿嘧啶(CAF疗法)用于治疗有四个或更多受累淋巴结的I、II或IIIa期乳腺癌女性患者的疗效。
Gan To Kagaku Ryoho. 2006 Oct;33(10):1423-9.
10
Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome.接受多模式治疗的腋窝淋巴结转移10个及以上的乳腺癌患者:临床表现对预后的影响。
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):364-9. doi: 10.1016/j.ijrobp.2006.12.027. Epub 2007 Feb 26.

引用本文的文献

1
Systematic review of breast cancer biology in developing countries (part 1): Africa, the middle East, eastern europe, Mexico, the Caribbean and South america.发展中国家乳腺癌生物学的系统评价(第 1 部分):非洲、中东、东欧、墨西哥、加勒比海和南美洲。
Cancers (Basel). 2011 May 13;3(2):2358-81. doi: 10.3390/cancers3022358.

[乳腺癌]

[Breast cancer].

作者信息

Caballero J L, Ríos B

机构信息

Servicio de Oncología Médica y Quimioterapia, Hospital Rafael Hernández, David, Chiriquí.

出版信息

Rev Med Panama. 1995 Jan-May;20(1-2):50-3.

PMID:7480904
Abstract

The authors reviewed the clinical records of 31 patients with carcinoma of the breast diagnosed at the Dr. Rafael Hernández Hospital in Chiriquí from January 1988 to December 1990. All the patients were women and the average age was 51.9 years. 41.9% of the patients were classified Stage 1; 29%, Stage 2; 16.1%, Stage IIIA; and 12.8%, Stage IIIB. 74% of the patients were treated with a modified radical mastectomy, radiation and hormonal therapies. Systemic cytotoxic therapy was given to 77% of the patients. Total survival 48 months after diagnosis was 83.3% in patients at Stage I; 66%, at Stage II; 40%, at Stage IIIA; and 0%, in patients at Stage IIIB.

摘要

作者回顾了1988年1月至1990年12月在奇里基省拉斐尔·埃尔南德斯博士医院确诊的31例乳腺癌患者的临床记录。所有患者均为女性,平均年龄为51.9岁。41.9%的患者被归类为1期;29%为2期;16.1%为IIIA期;12.8%为IIIB期。74%的患者接受了改良根治性乳房切除术、放疗和激素治疗。77%的患者接受了全身细胞毒性治疗。诊断后48个月的总生存率在I期患者中为83.3%;II期为66%;IIIA期为40%;IIIB期患者为0%。